Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of solid tumors. STRO-006 is the Company’s potential best-in-class integrin β6 (ITGB6)-targeting exatecan ADC with a drug-to-antibody ratio of 8 (DAR8), engineered for optimized pharmacokinetics, tolerability and a differentiated therapeutic index.

The Phase 1, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of STRO-006 in adults with advanced or metastatic solid tumors. The dose-escalation portion will enroll patients with ITGB6-expressing tumor types, including head and neck cancer, non-small cell lung cancer, esophageal/gastric cancer, colorectal cancer, endometrial cancer, urothelial cancer and breast cancer. The trial will evaluate STRO-006 across ascending dose levels beginning at 1.5 mg/kg. This starting dose is enabled by Sutro’s precise design capabilities and supported by the tolerability observed in non-human primates at doses up to 30 mg/kg.